Home
Live Updates
ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC : comparemela.com
ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC
ASCO 2024, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), JNJ-69086420 (JNJ-6420), Actinium-225 (225Ac), Targeting Human Kallikrein 2, JNJ-6420 adverse events.
Related Keywords
Memorial Sloan Kettering Cancer Center ,
New York ,
United States ,
Chicago ,
Illinois ,
Georgia ,
American ,
Michaelj Morris ,
Michael Morris ,
Zachary Klaassen ,
Twitter ,
American Society Of Clinical Oncology ,
Morris ,
Georgia Cancer Center ,
Clinical Oncology ,
Prostate Cancer Section Head ,
Urologic Oncologist ,
Associate Professor ,
Annual Meeting ,
comparemela.com © 2020. All Rights Reserved.